Global Follicle Stimulating Hormone (FSH) Sales Varied From 30354 K Doses In 2013 To 34092 K Doses In 2017
Wednesday, 13 Feb, 2019
Follicle stimulating hormone (FSH) is a hormone made by the pituitary gland that affects the gonads (female ovaries and males testes). It is mainly used to treat infertility disease and assisted reproductive technology. At present, this product cannot be replaced in the treatment of infertility.
There are two methods to produce follicle stimulating hormone, recombinant DNA technology and urine extraction technology. Due to less pollution, recombinant FSH takes large proportion in market. In 2017, recombinant FSH takes about 79.83%. While, recombinant DNA technology is difficult and there are only few company own this technology.
Currently, There are only several companies producing this product, such as Merck Serono, MSD, IBSA, Ferring, Livzon and Techwell etc. Merck Serono and MSD are top two companies in the world. In 2017, Merck Serono takes about 52.34% of global follicle stimulating hormone revenue. MSD takes about 19.15% of global follicle stimulating hormone revenue.
Global follicle stimulating hormone (FSH) mainly consumed in Asia Pacific, Europe and North America. In 2017, Asia Pacific follicle stimulating hormone (FSH) revenue takes about 24.81% in global. Europe takes 35.68% of global follicle stimulating hormone (FSH) revenue. North America takes 24.67%. The product has high degree of monopoly.
In the past five years, global follicle stimulating hormone (FSH) sales varied from 30354 K Doses in 2013 to 34092 K Doses in 2017, with an average increase rate of 2.95%. Meanwhile, global FSH revenue also varied from 1251.68 Million USD in 2013 to 1245.39 Million USD in 2017.
In the future, with increase of pressure from work, global Infertility patients may increase. So, global follicle stimulating hormone (FSH) demand will increase. By 2024, global follicle stimulating hormone (FSH) consumption will get to 52548 K Doses.